StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note released on Tuesday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Trading Down 3.2 %

Shares of NASDAQ:ADXS opened at $0.60 on Tuesday. Ayala Pharmaceuticals has a one year low of $0.51 and a one year high of $1.95. The company has a 50 day moving average of $0.74 and a 200-day moving average of $0.76.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.